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Abstract 
Equine herpesvirus type 1 (EHV-1) causes respiratory disease, abortion and neurological disorders in horses. Besides 
epithelial cells, CD172a+ monocytic cells become infected with EHV-1 in the respiratory mucosa and transport 
the virus from the apical side of the epithelium to the lamina propria en route to the lymph and blood circulation. 
Whether CD172a+ monocytic cells are specifically recruited to the infection sites in order to pick up virus is unknown. 
In our study, equine nasal mucosa explants were inoculated with EHV-1 neurological strains 03P37 and 95P105 or the 
non-neurological strains 97P70 and 94P247 and the migration of monocytic cells was examined by immunofluores-
cence. Further, the role of monokines CCL2 and CCL5 was determined and the effect of migration inhibitors rosiglita-
zone (RSG) or quinacrine was analyzed. It was shown that with neurological strains but not with the non-neurological 
strains, CD172a+ cells specifically migrated towards EHV-1 infected regions and that CCL2 and CCL5 were involved. 
CCL2 started to be expressed in infected epithelial cells at 24 h post-incubation (hpi) and CCL5 at 48 hpi, which corre-
sponded with the CD172a+ migration. RSG treatment of EHV-1-inoculated equine nasal mucosa had no effect on the 
virus replication in the epithelium, but decreased the migration of CD172a+ cells in the lamina propria. Overall, these 
findings bring new insights in the early pathogenesis of EHV-1 infections, illustrate differences between neurological 
and non-neurological strains and show the way for EHV-1 treatment.
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Equine herpesvirus 1 (EHV-1) is an important pathogen 
of horses. It is a member of the subfamily Alphaherpes-
virinae with a 150 kb double stranded DNA genome [1]. 
Alphaherpesviruses of different species have developed 
in evolution various ways to reach deeper tissues of the 
upper respiratory tract in order to find lymph and blood 
vessels for further spread and neurons for inducing 
latency. Among them, pseudorabies virus (PRV), bovine 
herpesvirus-1 (BHV-1) and herpes simplex virus-1 (HSV-
1) easily spread across the basement membrane (BM) 
in a plaquewise manner upon the activation of cellular 
proteases whereas EHV-1 employs a more discrete man-
ner to invade [2–4]. It hitchhikes across the BM using 
local immune cells, mainly CD172a+ cells as Trojan 
horse [5]. EHV-1 enters CD172a+ cells via an endocytic 
mechanism that requires cholesterol, tyrosine kinase 
activity, actin, dynamin activity and endosomal acidifi-
cation, pointing towards a phagocytic mechanism [6]. 
EHV-1 infection of nasal mucosa epithelial cells leads 
to an increase of the thickness of the collagen VII and a 
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degradation of integrin alpha 6 of the BM underneath the 
EHV-1 plaques [7]. Afterwards, a cell-associated viremia 
allows EHV-1 to reach internal organs such as the preg-
nant uterus and/or central nervous system (CNS). Rep-
lication in these organs may result in abortion, neonatal 
foal death and myeloencephalopathy [8, 9]. Based on the 
difference of a single nucleotide polymorphism (A2254/
G2254) in the EHV-1 DNA polymerase gene (ORF30), 
EHV-1 can be divided into neurological strains and non-
neurological strains [10]. It has been reported that the 
neurological strains infect a higher number of CD172a+ 
cells than the abortigenic strains in the upper respiratory 
mucosa [5].
Our lab has found that CD172a+ monocytic cells can 
become infected with EHV-1 in the respiratory mucosa 
and transport the virus from the apical side of the epi-
thelium to the lamina propria en route to the lymph 
and blood circulation [11]. In general, cytokines and 
chemokines are orchestrating the migration of monocytic 
cells during viral infections in the airways [12, 13]. It has 
been reported that infection of alveolar epithelial cells 
with influenza A virus can strongly induce the release of 
monocyte chemoattractants CCL2 and CCL5 followed 
by a strong recruitment of monocyte transepithelial 
migration [14]. Whether EHV-1 infection is activating 
the attraction of CD172a+ monocytic cells to the infec-
tion sites and whether CCL2 and CCL5 are driving forces 
during this process are largely unknown. In a previous 
study, it has been shown that EHV-1 infected PBMC can 
up-regulate inflammatory chemokines CCL5, CXCL9 
and CXCL10, and down-regulate chemotactic CCL2 and 
CCL3 with clear strain differences [15]. During an infec-
tion with another alphaherpesvirus, HSV-1, in mice, 
it has been reported that CCL3 attracts NK cells [16], 
CCL2 recruits monocytes [17], and CCL5 recruits mono-
cytes, NK cells, and PMNs [18] while CXCL9 recruits 
T-cells to the sites of infection [16, 19]. In our study, we 
mainly focused on the well-known monokines CCL2 and 
CCL5. IL-8/CXCL8 that can specifically induce neutro-
phil recruitment during an EHV-1 infection [20] was also 
included.
EHV-1 infection has a significant economical impact 
on the equine breeding industry worldwide every year 
[21]. Current vaccines do not provide full protection 
against severe symptoms induced by EHV-1 and there 
is no efficacious antiviral treatment available for EHV-1 
infection. As CD172a+ cells function as Trojan horses 
during EHV-1 invasion in the respiratory mucosa, inhibi-
tion of the recruitment of these cells may prevent migra-
tion of infected monocytic cells into the deep tissues. 
This might be an effective way to impede the generation 
and invasion of infected CD172a+ cells and reduce the 
viremia. Phenotypical and functional analysis of the nasal 
mucosal CD172a+ cells indicated that they mainly consist 
of immature dendritic cells (DC) [22].
Thus, DC migration inhibitors might be an option to 
inhibit the EHV-1 deep invasion. It has been demon-
strated that rosiglitazone (RSG), which has been used to 
treat type 2 diabetes, can specifically impair the depar-
ture of Langerhans cells (LCs) from the epidermis and 
moreover can block accumulation of DC in the draining 
lymph nodes (DLNs). In the respiratory mucosa, RSG 
can also inhibit the migration of DCs from the airway 
mucosa to the thoracic lymph nodes (LNs) [23]. Another 
DC migration inhibitor, quinacrine (QC), originally used 
as an antiprotozoal and anti-rheumatic agent, has also 
been reported to inhibit the epidermal DC migration by 
blocking NF-κB-dependent production of TNF-α, IL-1β 
and CCL21 in the skin [24].
In the current study, equine nasal mucosa explants 
were used as a model to study whether CD172a+ mono-
cytic cells are specifically recruited to the EHV-1 infec-
tion sites in order to capture virus and whether the 
monokines CCL2 and CCL5 are involved during this 
process. In addition, treatment with RSG or QC at dif-
ferent concentrations was performed 12 h prior to or at 
the same time of the viral inoculation to test whether the 
treatment can impede EHV-1 deeper infection.
Materials and methods
Cells and virus
RK-13 cells were used. They were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) (Invitrogen, Paisley, 
UK) supplemented with 10% fetal calf serum (Invitro-
gen), 100 U/mL penicillin, 0.1 mg/mL streptomycin and 
1 μg/mL gentamicin.
Four Belgian EHV-1 strains were used in this study. 
The neurovirulent strains 95P105 and 03P37 were origi-
nally isolated in 1995 and 2003 from the blood of a para-
lytic horse [25, 26] and the abortigenic strains 97P70 
and 94P247 strains were isolated in 1997 and 1994 from 
the lungs of an aborted fetus [27]. All the EHV-1 strains 
were at the sixth passage, four passages in equine embry-
onic lung cells and two subsequent passages in RK-13 
cells, with a titer of 106.5 tissue culture infectious dose 
with 50% endpoint per milliliter (TCID50/mL). For virus 
inactivation, a thin layer of viral suspension was exposed 
to short-wave UV light at 1.2 ×  105  µJ/cm2 for 10  min. 
Absence of viral infectivity was checked by virus titration 
on RK-13 cells.
Equine nasal mucosa explants and inoculation with EHV‑1
The nasal mucosa explants were collected from 3 healthy 
horses, between 4 and 6  years old at a local slaughter-
house. Firstly, the nasal mucosa explants were stripped 
from the nasal surface and divided into pieces of 50 mm2. 
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After 24  h of culture on fine-meshed gauze, explants 
were washed twice with warm medium and transferred 
on top of solid agarose. The margins were filled with 
agarose. Afterwards, the explants were inoculated with 
500  μL medium containing 106.5 TCID50 EHV-1 of the 
neurological strains 03P37 and 95P105 or the non-neu-
rological (abortigenic) strains 97P70 and 94P247 for 1 h 
at 37 °C with 5% CO2, respectively. After inoculation, the 
explants were rinsed and further incubated with fresh 
medium [28]. Mock inoculations, incubated with DMEM 
medium, were performed in parallel.
Localization and quantification of CD172a+ cells in equine 
nasal mucosa explants
At 0, 24, 48 and 72 h post-incubation (hpi) the explants 
were collected and snap frozen in methocel™. At each 
time point, 20 serial 16 µm cryosections were made for 
immunofluorescence stainings. In brief, biotinylated 
equine polyclonal anti-EHV-1 IgG (diluted 1:10 in PBS) 
[26], followed by streptavidin-Texas Red® (Invitrogen, 
1:200 in PBS) were added to check for EHV-1 infected 
cells. Next, mouse monoclonal antibody (mAb) DH59B 
(VMRD Inc., Pullman) was used as cell marker to detect 
CD172a+ cells, followed by FITC-labeled goat anti 
mouse IgG. The nuclei were counterstained with Hoe-
chst 33  342 (10  μg/mL, Molecular Probes). After stain-
ing, the cryosections were rinsed three times in PBS and 
mounted with glycerin/1,4-diazabicyclo [2.2.2] octane. 
All IF stainings were analyzed by confocal microscopy 
(Leica Microsystems GmbH, Wetzlar, Germany). An 
appropriate isotype-matched, irrelevant control (IgG1) 
mouse monoclonal anti-PRV gD antibody 13D12 was 
included for testing the specificity of the stainings [29]. 
Two regions of interest (ROI) were chosen for the quan-
tification of CD172a+ cells and EHV-1+ cells. One was 
the region where the epithelial cells were infected with 
EHV-1 (ROIWI) and the other was the region without 
EHV-1 infection in the epithelial cells (ROIWOI) (Fig-
ure 1). Three independent replicates were performed and 
20 images were taken for each experiment at each time 
point.
The expression of chemokines CCL2 and CCL5 in EHV‑1 
infected nasal mucosa explants
To check whether chemokines CCL2 and CCL5 may be 
involved in the recruitment of CD172a+ cells towards 
the infected epithelial cells, their expression was exam-
ined. The equine nasal mucosa explants were collected, 
cultured and inoculated with EHV-1 as described 
above. Mock inoculations were carried out in parallel. A 
scratch-wound assay using a yellow pipette tip to make a 
straight scratch and simulate a wound was performed to 
detect the expression of CCL2 or CCL5 in the wounded 
nasal mucosa explants. Inoculation with UV-inactivated 
EHV-1 was performed to test whether the production 
of CCL2 or CCL5 could be induced only by the binding/
entry step of EHV-1 to the epithelial cells. Finally, the 
explants were collected at 0, 24, 48 and 72 hpi, embedded 
in methocel™, and snap frozen at −70 °C.
Of each explant, 50 serial 16  µm cryosections were 
made for IF stainings and the aforementioned proto-
col was followed to detect EHV-1 infected cells. For the 
detection of CCL2 or CCL5, rabbit polyclonal anti-CCL2 
IgG or anti-CCL5 IgG (Biorbyt, 1:100 in PBS) was used as 
primary antibody, followed by goat anti-rabbit IgG FITC 
(1:100) (Invitrogen, 1:100 in PBS), respectively. The rabbit 
polyclonal anti-CXCL8 IgG (Mybiosource, 1:100 in PBS) 
was used as control. All the results of IF stainings were 
analyzed by confocal microscopy. By using the software 
imaging system ImageJ, the percentage of pixels posi-
tive for CCL2 or CCL5 was determined. Two ROIs were 
chosen for the quantification of the expression of CCL2 
or CCL5. One was the region where the epithelial cells 
were infected with EHV-1 (ROIWI) and the other was 
the region without EHV-1 infection in the epithelial cells 
(ROIWOI) (Figure  1). Three independent replicates were 
performed for each experiment.
Evaluation of tissue toxicity of rosiglitazone (RSG) 
and quinacrine (QC) on nasal mucosa explants
As DC migration inhibitors might be useful to inhibit 
the deep invasion of EHV-1 in respiratory mucosa via 
infected monocytic cells, two DC migration inhibitors 
RSG or QC (Sigma-Aldrich) were used to treat equine 
nasal mucosa explants. TUNEL staining was performed 
to assess the tissue toxicity of RSG or QC (1, 3, 10, 
30 μM) [23] on the nasal mucosa explants. Briefly, after 
24  h culture on fine-meshed gauze, these explants were 
transferred into 24-well plate and immersed with RSG or 
QC at different concentrations (1, 3, 10, 30 μM) for 1 h at 
Epithelium
Basement membrane (BM)
Lamina propria
ROIWI
ROIWOI
50 m Submucosa
Figure 1 EHV-1 neurological strain 03P37 infected equine 
nasal mucosa with two regions of interest. ROIWI is the region of 
interest including the epithelium and the lamina propria with EHV-1 
infection in the epithelium whereas ROIWOI is the region of interest 
without EHV-1 infection in the epithelium. The white line drawn 
on the image represents the basement membrane (BM). Scale bar: 
50 µm.
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37 °C with 5% CO2. Afterwards, the explants were trans-
ferred back to the gauze and cultured within the medium 
in the presence of RSG or QC at corresponding concen-
trations. Untreated explants were immersed in and incu-
bated with medium in the absence of RSG or QC. At 0, 
24, 48 and 72 hpi, the explants were collected and snap 
frozen in methocel™ at −70 °C. Cryosections were made 
and the TUNEL reaction was performed according to the 
manufacturer’s guidelines. TUNEL-positive cells were 
counted in five randomly chosen fields of 100 cells in the 
epithelium as well as in the lamina propria with confocal 
microscopy.
The effect of RSG or QC on EHV‑1 infection of nasal mucosa 
explants
The equine nasal mucosa explants were inoculated with 
EHV-1 neurological strains 03P37, 95P105 or non-neu-
rological strains 97P70, 94P247 and treated with RSG 
or QC (1, 3, 10, 30  μM), respectively. Mock inocula-
tions and treatments were carried out in parallel. The 
RSG or QC treatment was performed 12  h prior to or 
at the same time of EHV-1 inoculation, respectively. 
The supernatant of cultured explants was collected at 2, 
24, 48, 72 hpi for viral titration. The explants were col-
lected and snap frozen at 0, 24, 48, 72 hpi. Cryosections 
were made and IF stainings were performed to analyze 
EHV-1 infection by confocal microscopy. In the epithe-
lium, the plaque formation was analyzed. In the lamina 
propria of the mucosa, two regions of interest (ROI) 
were chosen for analysis of EHV-1 replication. One 
was the region where the epithelial cells were infected 
with EHV-1 (ROIWI) and the other was the region with-
out EHV-1 infection in the epithelial cells (ROIWOI). 
Three independent replicates were performed for each 
experiment.
The effect of RSG treatment on the distribution 
and numbers of CD172a+ cells in nasal mucosa explants 
infected with EHV‑1
The EHV-1 infected cell types in the lamina propria of 
which their recruitment was affected by treatment with 
RSG were identified by a double IF staining. For the 
staining of EHV-1, the protocol described above was fol-
lowed. To detect CD172a+ cells, CD5+ T lymphocytes or 
B lymphocytes (IgM+), mAbs DH59B, HT23A or 1.9/3.2 
(VMRD Inc., Pullman) were used as primary antibod-
ies and FITC-labeled goat anti-mouse IgG was used as 
secondary antibody. Proper controls were included for 
testing the specificity of the stainings. The nuclei were 
counterstained with Hoechst 33  342. All the stained 
cryosections were analyzed by confocal microscopy. 
Three independent replicates were performed for each 
experiment.
Data analysis
Three independent experiments were performed and 
the data are presented as means  ±  standard deviations 
(Givens and Marley).  ANOVA was used to calculate sta-
tistical significance among multiple groups. Data were 
classified: P  >  0.05, not significantly different; P  ≤  0.05 
(*), significantly different; P ≤ 0.01 (**), very significantly 
different; P ≤ 0.001 (***), extremely significantly different.
Results
The localization and quantification of CD172a+ cells in the 
equine nasal mucosa explants infected with EHV‑1
In mock-inoculated nasal mucosa, the CD172a+ cells 
were mainly localized in the lamina propria underneath 
the BM. In the epithelium, the CD172a+ cells were pre-
sent in a  scattered  manner (Figure  2A). Cultivation for 
72 h had no impact on the distribution and number of 
CD172a+ cells. For the neurological EHV-1 strain 03P37 
inoculated nasal mucosa explants, a basal to apical migra-
tion in the infected nasal mucosa area was observed. At 
24  hpi, EHV-1 infected CD172a+ cells were observed 
mainly in the epithelium and less frequently underneath 
the BM. There was no significant difference for the num-
ber of total CD172a+ cells in ROIWI or ROIWOI compared 
with the mock. At 48 hpi, more EHV-1 infected CD172a+ 
cells were found in the epithelium and a few underneath 
the BM. Compared with the mock, the number of total 
CD172a+ cells in the ROIWI was 30.5 ± 21.6% (P < 0.05) 
higher, while in the ROIWOI there was no significant dif-
ference (P > 0.05) (Figure 2B). At 72 hpi, nearly no EHV-1 
infected CD172a+ cells were found in the epithelium 
while there were much more EHV-1 infected CD172a+ 
cells observed underneath the BM. The number of total 
CD172a+ cells in the ROIWI was 44.2 ± 19.5% (P < 0.01) 
higher than that in the mock (Figure  2B). The percent-
age of EHV-1 positive cells in the population of CD172a+ 
positive cells in the ROIWI was 77.8 ±  31.5% (P  <  0.01) 
higher at 48  hpi and 76.8 ±  27.9% (P  <  0.01) higher at 
72  hpi compared with the ROIWOI (Figure  2C). Simi-
lar results were observed when inoculated with another 
EHV-1 neurological strain 95P105 (Additional file 1). For 
the EHV-1 non-neurological strains 97P70 and 94P247, 
there were no significant differences for the number and 
distribution of CD172a+ cells between ROIWI or ROI-
WOI and the mock at all time points (Figure 2; Additional 
file 1).
The expression of chemokine CCL2 and CCL5 in EHV‑1 
infected nasal mucosa explants
Both CCL2 and CCL5 positive cells were scattered 
underneath the epithelial cells of mock-inoculated 
nasal mucosal tissues at all the time points of cultiva-
tion, whereas CXCL8 positive cells were not observed 
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Figure 2 The localization and quantification of CD172a+ cells in equine nasal mucosa. The distribution (A) and the number (B) of CD172a+ 
cells in mock inoculated and EHV-1 neurological strain 03P37 and abortigenic strain 97P70 inoculated nasal mucosa at 0, 24, 48 and 72 hpi. C The 
percentage of EHV-1 infected cells in the population of CD172a+ cells in the nasal mucosa. ROIWI is the region including the epithelium and the 
lamina propria with EHV-1 infection in the epithelium whereas ROIWOI is the region without EHV-1 infection in the epithelium (two-way ANOVA; 
*P < 0.05; **P < 0.01). EHV-1 infected cells (red); CD172a+ cells (green). The white line drawn on the image represents the BM. Scale bar: 50 µm.
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(Figures  3A  and B). Upon inoculation with the EHV-1 
neurological strain 03P37, the expression of CCL2 
and CCL5 strongly increased and colocalized with the 
EHV-1 infected epithelial cells (Figures  3A  and B). The 
total expression of CCL2 was much higher than that of 
CCL5. The expression of CCL2 in nasal mucosa at ROIWI 
increased eightfold (P < 0.01) compared to the mock at 24 
hpi, ninefold (P < 0.01) at 48 hpi and 11-fold (P < 0.001) at 
72 hpi (Figure 3A). For CCL5, its expression in the ROIWI 
of the nasal mucosa explant inoculated with EHV-1 
was fourfold (P  <  0.01) and eightfold (P  <  0.01) higher 
than the mock at 48  hpi and 72  hpi, respectively (Fig-
ure 3B). There were no significant differences (P > 0.05) 
for CCL2 and CCL5 production between EHV-1 (ROI-
WOI), UV-EHV-1 and mock-inoculated explants at all the 
time points mentioned. The neurological strain 95P105 
showed similar results as strain 03P37 (Additional file 2). 
For nasal mucosa inoculated with the non-neurologi-
cal EHV-1 strains 97P70 and 94P247, the expression of 
CCL2 and CCL5 was not significantly different compared 
with mock-inoculated nasal mucosa (Figure 3; Additional 
file 2). CCL2 and CCL5 positive cells were distributed in 
a scattered way underneath the epithelium in the nasal 
mucosa in scratch-wound assay and their expression was 
similar with the mock (data not shown).
Viability analysis during treatment with RSG or QC 
in in vitro cultures
Apoptotic cell death was detected at different concentra-
tions (1, 3, 10, 30 μM) with RSG or QC. The number of 
apoptotic cells in the epithelium had a slight, but not sig-
nificant increase during the 72 h cultivation period with 
both products. The number of apoptotic cells in the epi-
thelium did not increase significantly for either RSG or 
QC (Table 1, only the data at 72 hpi were shown).
The effect of RSG or QC on EHV‑1 infection in nasal mucosa 
explants
During RSG or QC 12  h pre-treatment or treatment at 
the same time with the neurological EHV-1 strain 03P37 
inoculation, the viral titers in the supernatant of cultured 
explants and the plaque formation in the epithelium were 
similar, so only the data of RSG or QC treatment at the 
same time with EHV-1 inoculation were shown. Viral 
titers (Figure 4A) and plaque formation among different 
concentrations of RSG and QC treatment did not differ 
significantly (Figure  4B). In the lamina propria of nasal 
mucosa infected with the neurological 03P37 strain, the 
number of EHV-1 infected cells was remarkably lower 
at 72  hpi when treated with RSG 12  h before inocula-
tion or at the same time, with 41.2  ±  11.7% (P  <  0.01) 
or 30.3  ±  8.2% (P  <  0.05) at 10 μM and 67.2  ±  9.8% 
(P < 0.001) or 54.5 ± 16.8% (P < 0.01) at 30 μM for the 
ROIWI (Figure 4C). This lower number of EHV-1 infected 
cells was not observed when treated with QC. The neu-
rological strain 95P105 showed similar results as strain 
03P37. For strain 97P70 and 94P247, pre-treatment and 
treatment with RSG or QC did not change virus replica-
tion in the epithelium and the number of EHV-1 infected 
cells in the lamina propria (Additional file 3, only the data 
for strain 97P70).
The RSG treatment inhibited the migration of CD172a+ 
cells in the EHV‑1 inoculated nasal mucosa explants
In the mock-inoculated explants and EHV-1-inoculated 
explants, the RSG pretreatment or treatment at the same 
time had no effect on the number of CD5+ T and B-lym-
phocytes in the lamina propria. Within the mock-inoc-
ulated explants, the RSG pretreatment or treatment at 
the same time had no effect on the number of CD172a+ 
cells in the lamina propria (Figure  5B). In the EHV-
1-inoculated explants, at 72  hpi, in the lamina propria 
of ROIWI the number of total CD172a+ cells decreased 
with 28.9 ± 6.5% (P < 0.01) or 41.3 ± 9.6% (P < 0.01) at a 
pretreatment with 10 or 30 μM. When treated with RSG 
at the same time of EHV-1 inoculation, the number of 
total CD172a+ cells in the lamina propria of ROIWI was 
reduced with 31.1 ± 7.6% (P < 0.01) at the concentration 
of 30  μM (Figure  5C). The neurological strain 95P105 
showed similar results as strain 03P37 (Additional file 4).
Discussion
Monocytic cells play an important role in the pathogen-
esis of EHV-1 infection [6]. CD172a+ monocytic cells 
become infected with EHV-1 in the nasal mucosa (the 
initial infection site), and transport the virus from the 
apical side of the epithelium into the deep lamina pro-
pria [11]. Our data demonstrate that a basal to apical side 
migration of non-infected CD172a+ cells was present 
during the early stage of the EHV-1 neurological strain 
infection in the epithelial cells. Indeed, at 24 and 48 hpi, 
CD172a+ cells migrated towards the infected epithelium 
region as fewer CD172a+ cells were observed underneath 
the BM while more infected CD172a+ cells were present 
in the epithelium at these time points. In the infected 
regions more CD172a+ cells were found at 48 and 72 hpi, 
most probably due to migration from deeper tissues, 
as there was no reduction of CD172a+ cells in the area 
lateral from the infected regions. More EHV-1 infected 
CD172a+ cells gathered in the lamina propria at 72 hpi, 
which indicated that after getting in contact with the 
virus, the infected CD172a+ cells migrated into the deep 
regions for further invasion. It has also been reported 
that a basal-to-apical monocyte transepithelial migra-
tion in vitro can be elicited by influenza A virus infection 
of primary alveolar epithelial cells and resident alveolar 
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Figure 3 The expression of CCL2 and CCL5 in EHV-1 infected nasal mucosa. The expression of CCL2 (A) and CCL5 (B) in mock inoculated, 
EHV-1 neurological strain 03P37 and abortigenic strain 97P70 inoculated (at ROIWI and ROIWOI) as well as their UV inactivated viruses (UV-03P37 
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macrophages, which can be induced by monocyte che-
moattractants CCL2 and CCL5 [14, 30]. Chemokines 
are secreted in response to signals such as proinflam-
matory cytokines where they play an important role in 
selectively recruiting monocytes, neutrophils, and lym-
phocytes. Monocyte chemoattractant protein-1 (MCP-1/
CCL2) can be secreted by epithelial cells and many 
immune cells including monocytes and DC and is one 
of the key chemokines that regulate migration and infil-
tration of monocytes/macrophages [31, 32]. CCL5, pre-
viously known as RANTES (regulated upon activation, 
normal T cell expressed and secreted) is a member of 
the CC chemokine family. It can be produced by T lym-
phocytes, tumor cells and fibroblasts and recruits mono-
cytes, T cells, basophils and eosinophils [33]. The current 
data in our study showed that the neurological EHV-1 
infected nasal mucosa explants displayed a release of 
both CCL2 and CCL5. The CCL2 started to be expressed 
in the epithelial cells at 24  hpi, which is corresponding 
with the time point when the number of CD172a+ cells 
in the lamina propria decreased. This indicates that the 
secreted CCL2 is most probably involved in the recruit-
ment of CD172a+ cells during an infection with EHV-1 
neurological strains. The basal to apical migration and 
chemokine production were shown for neurological 
strains but not for the non-neurological strains. This 
strain specificity may be linked with the cell tropism of 
EHV-1. For the neurological strain 03P37, the majority 
of individual infected cells were CD172a+ cells while for 
the non-neurological strain 97P70, individual infected 
cells were equally identified as CD5+ T lymphocytes and 
CD172a+ cells [5]. For CD5+ T lymphocytes attraction, 
other chemokines such as, CXCL9 and CXCL10 [16, 19] 
may be involved. Current research is looking into the 
involvement of these T lymphocytic chemokines in the 
early pathogenesis of non-neurological EHV-1 strains. 
For the difference between neurological strains and non-
neurological strains, there is a hypothesis that the muta-
tion in ORF30 (DNA polymerase, A2254/G2254), which 
results in a modified DNA polymerase activity, enhances 
the virulence of this viral strain [10]. However, there is 
compelling evidence that this nucleotide substitution 
is not the only determinant for the induction of neuro-
logical disease by EHV-1 [34]. Not only ORF30, but also 
other ORFs may have an impact on the viral replication 
rate, with potential concomitant effects on neuropatho-
genicity [35]. This still needs to be further examined.
Absence of CCL2 and CCL5 expression in the wound-
scratch assay indicated that cell death induced by wound-
ing was not responsible for or at least, had no direct 
impact on their expression. CCL2 and CCL5 were not 
detected when inoculated with UV inactivated EHV-
1. This demonstrated that the step of binding to and 
entry into host cells is not sufficient for the produc-
tion of CCL2 and CCL5. A further stage, including viral 
gene expression and replication is necessary for their 
expression. The production of CCL2 and CCL5 was first 
detected at 24  hpi in the nasal mucosa infected with 
EHV-1. At 12 hpi, there was nothing observed (data not 
shown). This indicates that the chemokines CCL2 and 
CCL5 become expressed between 12 and 24  hpi. This 
is the time period during which some late viral proteins 
become expressed in epithelial cells and CD172a+ cells 
[36, 37]. It seems to indicate that some late viral pro-
teins or transcription factors are involved in the induc-
tion of CCL2 and CCL5 expression. It has been reported 
that human cytomegalovirus (HCMV) tegument pro-
tein pp71 [38] and the viral G protein coupled receptor 
(vGPCR) of human herpesvirus 8 (HHV-8) lead to an 
increased expression of CCL2 during infection [39]. In 
addition, HHV-8 upregulates activating transcription 
factor 4 (ATF4) expression, which induces CCL2 produc-
tion in endothelial cells [40]. RNase protection analyses 
revealed increased expression of CCL2 at 8 and 12  hpi 
with EHV-1 strain KyARgp2F (an EHV-1 recombinant 
strain from KyA, expressing the full-length gp2 protein) 
compared to EHV-1 strain KyA (harbors part of gp2 pro-
tein) when infecting mice [41]. It is very well possible 
that the full-length gp2 protein is involved in the induc-
tion of CCL2 in the early stage of infection. The differ-
ence of the time points may be explained by the fact that 
our detection was on the protein level, which is later than 
Table 1 Absence of toxicity of RSG and QC in nasal mucosa explants
Viability of nasal mucosa explants treated with RSG or QC at different concentrations was determined in the TUNEL assay at 72 hpi. Values are given as mean ± SD of 3 
different experiments.
Localization (nasal mucosa) Products Percentage (%) of TUNEL‑positive cells treated at… μM at 72 hpi
0 (mock) 1 3 10 30
Epithelium RSG 0.3 ± 0.2 0.4 ± 0.3 0.7 ± 0.6 0.6 ± 0.5 1.1 ± 0.6
QC 0.4 ± 0.1 0.7 ± 0.3 1.2 ± 0.6 1.4 ± 0.6 1.6 ± 0.7
Lamina propria RSG 0.5 ± 0.6 1.4 ± 0.8 3.0 ± 0.7 2.8 ± 1.9 4.0 ± 1.1
QC 0.6 ± 0.2 1.2 ± 0.7 2.7 ± 0.9 3.2 ± 0.7 4.7 ± 1.6
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Figure 4 Viral production and plaque formation of EHV-1 in equine nasal mucosa. Viral production (A) at 0, 2, 24, 48 and 72 hpi and plaque 
formation (B) at 72 hpi in nasal mucosa explants inoculated with EHV-1 neurological strain 03P37 and treated at the same time with RSG or QC at 
different concentrations (1 μM, 3 μM, 10 μM, 30 μM). The number of individual EHV-1 infected cell in the lamina propria of nasal mucosa explants 
(C) treated with RSG or QC 12 h prior to or at the same time of EHV-1 inoculation. ROIWI is the region of interest including the epithelium and the 
lamina propria with EHV-1 infection in the epithelium whereas ROIWOI is the region of interest without EHV-1 infection in the epithelium (two-way 
ANOVA; **P < 0.01; ***P < 0.001) 
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Figure 5 The localization and quantification of CD172a+ cells in the lamina propria treated with RSG. The distribution (A) and the num-
ber of CD172a+ cells in the lamina propria of mock-inoculated (B) or EHV-1 neurological strain 03P37 inoculated (C) nasal mucosa explants at 72 hpi 
and treated with RSG 12 h prior to or at the same time of the mock or viral inoculation at a concentration of 10 μM or 30 μM. ROIWI is the region of 
interest including the epithelium and the lamina propria with EHV-1 infection in the epithelium whereas ROIWOI is the region of interest without 
EHV-1 infection in the epithelium (two-way ANOVA; *P < 0.05; **P < 0.01). EHV-1 infected cells (red); CD172a+ cells (green). The white line drawn on 
the image represents the BM. Scale bar: 50 µm.
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the detection of RNA transcripts. Except for gp2 pro-
tein, other EHV-1 viral proteins and transcription factors 
involved in the CCL2 and CCL5 induction also need to 
be further identified.
As we have observed the migration of CD172a+ cells 
during the EHV-1 infection in the nasal mucosa, migra-
tion inhibitors were used to treat the nasal mucosa. The 
treatment with RSG of equine nasal mucosa had no 
impact on the virus replication in the epithelium while 
the number of infected CD172a+ cells in the lamina pro-
pria decreased when treated with RSG at 10 and 30 μM. 
A possible explanation is that RSG treatment can inhibit 
the migration of CD172a+ cells in a dose-dependent 
manner during an EHV-1 infection. It showed that the 
migration of CD172a+ cells from the deeper tissues 
towards the infected region was inhibited in our study. 
This is in agreement with the research of Kintscher et al. 
[42], demonstrating that RSG function as peroxisome 
proliferator-activated receptor (PPAR) γ agonist and the 
activation of PPAR γ could impede DC migration from 
the peripheral sites of antigen capture to the DLNs. PPAR 
γ activation could also play a role in the spontaneous 
migration of intramucosal DCs and reduced migration 
of mice lung DCs under steady state conditions without 
infection [23, 43]. Our data showed that only in the con-
dition with EHV-1 infection, the RSG treatment could 
inhibit the migration of CD172a+ cells, whereas no inhib-
itory impact was observed with mock-inoculation and 
RSG treatment. This may be due to the species specificity 
and the difference between in vivo and ex vivo cultures.
In conclusion, we have demonstrated that a basal to 
apical migration of CD172a+ cells in nasal mucosa was 
present during infections with neurological EHV-1 
strains, with CCL2 and CCL5 involved in the attrac-
tion of CD172a+ cells towards the infected regions. 
RSG treatment efficiently inhibited the CD172a+ cells 
migration in a dose-dependent manner while it had no 
effect on the virus replication in the epithelium. A better 
understanding of the viral and cellular factors during this 
process could give new insights into the early pathogen-
esis of an infection with neurological EHV-1 and provide 
future therapeutic strategies.
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Additional file 1. The quantification of CD172a+ cells in equine 
nasal mucosa. (A) The number of CD172a+ cells in mock inoculated and 
EHV-1 neurological strain 95P105 and abortigenic strain 94P247 inocu-
lated nasal mucosa at 0, 24, 48 and 72 hpi. (B) The percentage of EHV-1 
infected cells in the population of CD172a+ cells in the nasal mucosa. 
ROIWI is the region including the epithelium and the lamina propria with 
EHV-1 infection in the epithelium whereas ROIWOI is the region with-
out EHV-1 infection in the epithelium (Two-way ANOVA; *: P < 0.05; **: 
P < 0.01).
Additional file 2. The expression of CCL2 and CCL5 in EHV-1 
infected nasal mucosa. The expression of CCL2 (A) and CCL5 (B) in 
mock inoculated, EHV-1 neurological strain 95P105 and abortigenic strain 
94P247 inoculated (at ROIWI and ROIWOI) as well as their UV inactivated 
viruses 95P105 and 94P247 inoculated nasal mucosa at 0, 24, 48 and 72 
hpi (Two-way ANOVA; **: P < 0.01; ***: P < 0.001).
Additional file 3. Viral production and plaque formation of EHV-1 
in nasal mucosa. Viral production (A) at 0, 2, 24, 48 and 72 hpi and 
plaque formation (B) at 72 hpi in nasal mucosa explants inoculated with 
EHV-1 abortigenic strain 97P70 and treated at the same time with RSG or 
QC at different concentrations (1 μM, 3 μM, 10 μM, 30 μM). The number 
of individual EHV-1 infected cells in the lamina propria of nasal mucosa 
explants (C) treated with RSG or QC 12 h prior to or at the same time of 
EHV-1 inoculation. ROIWI is the region of interest including the epithelium 
and the lamina propria with EHV-1 infection in the epithelium whereas 
ROIWOI is the region of interest without EHV-1 infection in the epithelium 
(Two-way ANOVA; **: P < 0.01; ***: P < 0.001).
Additional file 4. The quantification of CD172a+ cells in the lamina 
propria treated with RSG. The number of CD172a+ cells in the lamina 
propria of EHV-1 neurological strain 95P105 inoculated nasal mucosa 
explants at 72hpi treated with RSG 12 h prior to (A) or at the same time 
(B) of the mock or viral inoculation at a concentration of 10 μM or 30 μM. 
ROIWI is the region of interest including the epithelium and the lamina 
propria with EHV-1 infection in the epithelium whereas ROIWOI is the 
region of interest without EHV-1 infection in the epithelium (Two-way 
ANOVA; *: P < 0.05; **: P < 0.01).
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